- Home
- WYY vs RADX Comparison
WYY vs RADX Comparison
Compare WYY & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYY
- RADX
- Stock Information
- Founded
- WYY 1991
- RADX 2021
- Country
- WYY United States
- RADX Australia
- Employees
- WYY N/A
- RADX N/A
- Industry
- WYY EDP Services
- RADX
- Sector
- WYY Technology
- RADX
- Exchange
- WYY Nasdaq
- RADX NYSE
- Market Cap
- WYY 33.6M
- RADX 32.5M
- IPO Year
- WYY 1998
- RADX N/A
- Fundamental
- Price
- WYY $2.99
- RADX $4.64
- Analyst Decision
- WYY Strong Buy
- RADX Strong Buy
- Analyst Count
- WYY 1
- RADX 3
- Target Price
- WYY $7.00
- RADX $15.00
- AVG Volume (30 Days)
- WYY 58.6K
- RADX 17.9K
- Earning Date
- WYY 08-14-2025
- RADX 02-26-2025
- Dividend Yield
- WYY N/A
- RADX N/A
- EPS Growth
- WYY N/A
- RADX N/A
- EPS
- WYY N/A
- RADX N/A
- Revenue
- WYY $142,582,209.00
- RADX $204,609.00
- Revenue This Year
- WYY $9.05
- RADX N/A
- Revenue Next Year
- WYY $12.24
- RADX N/A
- P/E Ratio
- WYY N/A
- RADX N/A
- Revenue Growth
- WYY 24.03
- RADX N/A
- 52 Week Low
- WYY $2.19
- RADX $3.50
- 52 Week High
- WYY $6.25
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- WYY 34.63
- RADX N/A
- Support Level
- WYY $2.99
- RADX N/A
- Resistance Level
- WYY $3.23
- RADX N/A
- Average True Range (ATR)
- WYY 0.18
- RADX 0.00
- MACD
- WYY -0.01
- RADX 0.00
- Stochastic Oscillator
- WYY 1.75
- RADX 0.00
About WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.